Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics presented preclinical findings at the Society for Immunotherapy of Cancer Annual Meeting, highlighting the potential of combining selective adenosine A2B and A2A antagonists with cancer vaccines to enhance immune response [1][2][3] Research Findings - The studies conducted by the National Cancer Institute demonstrated that the combination of TT-4 (A2B antagonist) and TT-10 (A2A antagonist) with therapeutic vaccines resulted in significant tumor growth suppression and improved survival rates in mouse models [2] - In the TC1 lung cancer model, the triple combination of TT-4, TT-10, and an E7 peptide vaccine led to complete tumor regression in several mice, showcasing the potential for these treatments to translate to human applications [2] Clinical Development Status - TT-4 is an IND-enabled program with mesothelioma as the lead indication, preparing for first-patient dosing in Q1 2026 [4] - TT-10 is currently undergoing Phase 1 dose escalation trials in patients with advanced solid tumors [4] Strategic Goals - The collaboration with NCI reflects a long-term effort to enhance vaccine-driven immunity through the co-administration of selective receptor antagonists [3] - AlphaTON aims to leverage these preclinical data to guide capital deployment and partnerships for advancing TT-4 and TT-10 in clinical settings [3][10]

Core Insights - IO Biotech will hold a conference call and webcast on August 11, 2025, to disclose topline results from the pivotal Phase 3 trial of its cancer vaccine Cylembio [1][2] - Cylembio is being tested in combination with pembrolizumab for the treatment of unresectable or metastatic melanoma [1][3] - The company is advancing its lead candidate Cylembio and has received Breakthrough Therapy Designation from the FDA for another candidate in combination with KEYTRUDA [3] Company Overview - IO Biotech is a clinical-stage biopharmaceutical company focused on developing immune-modulatory, off-the-shelf therapeutic cancer vaccines using its T-win® platform [3] - The T-win platform aims to activate T cells to target tumor cells and immune-suppressive cells in the tumor microenvironment [3] - The company is headquartered in Copenhagen, Denmark, with a US office in New York [3]